One‐Day Brentuximab–Bendamustine (120 mg/m2) Every 21 Days is a Feasible, Safe and Effective Treatment for Relapsed/Refractory Hodgkin Lymphoma
Hematological Oncology · 2025
DOI: 10.1002/hon.70031 ↗Kurz gefasst
Leserbrief in der Zeitschrift Hematological Oncology, 2025. Verfasst von H Moatti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Hématologie, Centre Hospitalier Annecy Genevois, Epagny-Metz-Tessy, France. Hauptthemen laut MEDLINE: Hodgkin Disease, Brentuximab Vedotin, Bendamustine Hydrochloride, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Brentuximab vedotin (BV)‐bendamustine (90 or 120 mg/m2 day 1 and 2) every 28 days is an effective treatment for relapsed/refractory Hodgkin lymphoma (R/R HL) but associated to high toxicity especially for elderly patients. We conducted in St Louis Hospital, Paris, between 2015 and 2021 a retrospective single‐center analysis of 44 patients with R/R HL treated with one‐day BV‐bendamustine (120 mg/m2) every 21 days. Sixteen percent of patients were ≥ 60 years old (yo). Seventy‐three percent of patients received total number of cycles without interruption nor adaptation. No patient ≥ 70 yo required treatment interruption. Dose adjustment was necessary for 18% of patients. Infusion‐related reaction (36%) occurred always at cycle 2 and was the only cause of treatment interruption. One febrile neutropenia, one non‐documented septic shock, one pyelonephritis on transplanted kidney and one COVID complicated by cytopenias were reported. Sixteen percent patients presented a peripheral sensory neuropathy, 7% and 4% respectively grade 3–4 neutropenia and thrombocytopenia. Overall response was 84%, with 73% of complete remission. Median progression‐free survival was of 19.8 months (95% CI 13.1‐NR) and median overall survival was not reached with a median follow‐up of 31 months. We suggest that one‐day BV‐bendamustine (120 mg/m2) ever 21 days is a safe and feasible treatment for R/R HL especially for elderly patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service d'Hématologie, Centre Hospitalier Annecy Genevois, Epagny-Metz-Tessy, France.
- Service d'Hémato-Oncologie, APHP, Hôpital St Louis, Paris, France.
- Service d'Hématologie, Centre Hospitalier de Brive, Brive-la-Gaillarde, France.
- Service d'Hématologie Clinique, APHP, Hôpital Henri-Mondor, Créteil, France.
- Service de Direction de la Recherche Clinique, Centre Hospitalier Annecy Genevois, Epagny-Metz-Tessy, France.
- Pharmacie, APHP, Hôpital St Louis, Paris, France.
Zitieren
APA
Moatti, H., Brice, P., Laroque, M. C., Di Blasi, R., Wencel, J., Delory, T., Madelaine-Chambrin, I., Schmidt-Hieber, C., Ravdan, O., Thieblemont, C., & Renaud, L. (2025). One‐Day Brentuximab–Bendamustine (120 mg/m2) Every 21 Days is a Feasible, Safe and Effective Treatment for Relapsed/Refractory Hodgkin Lymphoma. Hematological Oncology. https://doi.org/10.1002/hon.70031
Vancouver
Moatti H, Brice P, Laroque MC, Di Blasi R, Wencel J, Delory T, et al. One‐Day Brentuximab–Bendamustine (120 mg/m2) Every 21 Days is a Feasible, Safe and Effective Treatment for Relapsed/Refractory Hodgkin Lymphoma. Hematological Oncology. 2025. doi:10.1002/hon.70031
BibTeX
@article{Moatti2025,
author = {Moatti, H and Brice, P and Laroque, M-C and Di Blasi, R and Wencel, J and Delory, T and Madelaine-Chambrin, I and Schmidt-Hieber, C and Ravdan, O and Thieblemont, C and Renaud, L},
title = {One‐Day Brentuximab–Bendamustine (120 mg/m2) Every 21 Days is a Feasible, Safe and Effective Treatment for Relapsed/Refractory Hodgkin Lymphoma},
journal = {Hematological Oncology},
year = {2025},
doi = {10.1002/hon.70031}
}
EUVIMED